Program Description

Join a presentation from one of your peers on the efficacy, safety, dosing, and administration of once-weekly Zepbound®. Learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to ask questions at the conclusion of the program. Refreshments will be provided.

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Program Objectives

Upon completion of the program, participants will have learned the following about Zepbound:

• Mechanism of action.
• Clinical trial data, including efficacy and safety findings.
• Dosing and administration information.
• How to get appropriate patients started.

Registration is not necessary. For compliance reasons, the sponsor will close the doors 10 minutes after the presentation begins.

Discover how the RENOVATE Randomized Clinical Trial uses Bayesian modeling to compare nasal high flow therapy (NHF) and non-invasive ventilation (NIV) in five cohorts of acute respiratory failure. This session highlights key clinical outcomes and their impact on managing different respiratory phenotypes. Learn to distinguish between NHF and NIV in practice and gain practical strategies for integrating NHF into care protocols, including early initiation and weaning. Perfect for clinicians aiming to enhance patient outcomes with evidence-based respiratory therapy.

Each speaker will share their experience implementing all-nebulization strategies in their hospitals.